Because we're in a net loss position, all share and per share amounts are the same for basic and diluted. In Q2, adjusted free cash flow was negative $5,600,000 resulting in a cash balance of $55,700,000 We previously commented on our free cash flow objectives for the year, noting that there would be variability from quarter to quarter and we will continue to manage our cost structure and GAAP billings of $70,000,000 to 75,000,000 to 75,000,000 to 75,000,000 to Q3, we're expecting non GAAP billings of $70,000,000 to $75,000,000 We expect Q3 GAAP revenue to be in the range of $77,000,000 to $78,000,000 We expect non GAAP net loss per share of $0.14 to $0.18 assuming 38,900,000 weighted average shares outstanding. For the full year, we expect billings of approximately 305,000,000 to 315,000,000 and GAAP revenue of 313,000,000 to 315,000,000 dollars For the full year, we expect non GAAP net loss per share basic and diluted of $0.69 to $0.77 This assumes 38,500,000 weighted average shares outstanding basic and diluted. Our guidance range reflects the variability that may result from making decisions that will benefit longer term growth at the expense of short term billings as we did this quarter with the 8 figure contract.